10-Q: Pasithea Therapeutics Q3 2025: Clinical Progress Amidst Liquidity Concerns

Pasithea Therapeutics reports continued clinical trial advancements for PAS-004 but faces significant operating losses and a going concern warning, necessitating further capital raises.

Summary

• Net loss for the nine months ended September 30, 2025, was $(10,316,815), an improvement from $(10,726,923) in the prior year period.
• Cash and cash equivalents stood at $4,122,953 as of September 30, 2025, down from $6,922,729 at December 31, 2024.
• Working capital decreased to $4,152,115 from $6,248,444 over the same period.
• Research and development expenses decreased by 8% to $5,236,320 for the nine months ended September 30, 2025, primarily due to de-prioritization of discovery programs, offset by increased clinical trial costs for PAS-004.
• General and administrative expenses increased by 1% to $5,364,813 for the nine months ended September 30, 2025.
• The company initiated a Phase 1/1b clinical trial for PAS-004 in adult NF1-PN patients in May 2025, with enrollment and initial dosing completed for the first cohort by July 2025.
• Activated two clinical trial sites in South Korea (September 2025) and one in the U.S. (November 2025) for the adult NF1-PN trial.
• Completed enrollment and initial dosing for cohort 6 of the FIH Phase 1 Dose Escalation Study for PAS-004 in April 2025, demonstrating robust target engagement in May 2025.
• The company raised approximately $2.0 million net from ATM sales and $4.2 million net from a May 2025 Public Offering, plus $1.3 million from warrant exercises, totaling $7.1 million in financing activities for the nine months ended September 30, 2025.

Sentiment

Score: 3

Explanation: While there is clinical progress with PAS-004, the severe liquidity issues, explicit going concern warning, and continued significant operating losses overshadow these advancements. The need for immediate and substantial capital raises, coupled with the "baby shelf rules" limitation, presents a high degree of financial risk.

Positives

• Net loss for the nine months ended September 30, 2025, improved to $(10.3) million from $(10.7) million in the prior year.
• Net cash used in operating activities improved to $(9.8) million for the nine months ended September 30, 2025, from $(11.5) million in the prior year.
• Successful initiation and progress of the Phase 1/1b clinical trial for PAS-004 in adult NF1-PN patients, including enrollment and site activations in Australia, South Korea, and the United States.
• Completion of enrollment and initial dosing for cohort 6 of the FIH Phase 1 Dose Escalation Study for PAS-004, with robust target engagement demonstrated.
• Successful capital raises through ATM sales ($2.0 million net), a May 2025 Public Offering ($4.2 million net), and warrant exercises ($1.3 million gross), providing $7.1 million in financing activities for the nine months ended September 30, 2025.
• Basic and diluted loss per share significantly improved to $(2.02) for the nine months ended September 30, 2025, from $(10.28) in the prior year, primarily due to an increased weighted-average common shares outstanding.

Negatives

• The company incurred a net loss of $(3,037,420) for the three months ended September 30, 2025, and $(10,316,815) for the nine months ended September 30, 2025.
• Cash and cash equivalents decreased to $4,122,953 as of September 30, 2025, from $6,922,729 at December 31, 2024.
• Working capital decreased by approximately $2.1 million, from $6,248,444 at December 31, 2024, to $4,152,115 at September 30, 2025.
• Accumulated deficit increased to approximately $(59,899,593) as of September 30, 2025.
• General and administrative expenses increased by 23% for the three months ended September 30, 2025, compared to the prior year period, driven by legal, corporate, and public company expenses.
• The company recorded a $102,000 loss from the sale of medical and office equipment during the three months ended September 30, 2025.
• Experienced higher costs due to inflation, with an anticipated negative impact throughout 2025.

Risks

• Substantial doubt about the company's ability to continue as a going concern through the next twelve months without additional funding.
• The company has incurred significant operating losses and negative cash flows from operations since inception and expects to continue incurring significant expenses and operating losses for the foreseeable future.
• Dependence on obtaining additional working capital funding from the sale of equity and/or debt securities, which may not be available on acceptable terms or at all.
• Failure to raise capital could lead to significant delays, scaling back, or discontinuation of product candidate development and commercialization.
• The development and commercialization of product candidates involve a lengthy and expensive process with an uncertain outcome.
• The company's public float is below $75.0 million, restricting primary public offerings of securities using shelf registration statements to one-third of its public float in any twelve-month period ("baby shelf rules").
• Exposure to higher costs due to inflation, with uncertainty on offsetting these pressures in the near term.
• The healthcare industry is subject to numerous laws and regulations, and compliance can be subject to future government review and interpretation, potentially resulting in significant fines or penalties.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances product candidates through development and clinical trials, and potentially commercialization. General and administrative expenses are expected to increase throughout fiscal year 2025 due to increased non-cash stock-based compensation. Research and development expenses are also projected to increase in fiscal year 2025, driven by higher clinical research costs for PAS-004's ongoing studies and increased manufacturing costs for drug supply, partially offset by reduced preclinical research and workforce reductions from laboratory closure. Management believes current working capital is insufficient to meet needs for the next twelve months without additional funding.

Management Comments

• "Management believes that the Company will not have sufficient working capital to meet its needs through twelve months from the date of these financial statements if additional funding cannot be obtained."
• "Without additional funding, there is substantial doubt about the Company’s ability to continue as a going concern through twelve months from the date of these financial statements."
• "We expect general and administrative expenses to increase throughout fiscal year 2025 as compared to fiscal year 2024 primarily due to increased non-cash stock-based compensation expenses."
• "We expect research and development expenses to increase throughout fiscal year 2025 as compared to fiscal year 2024 primarily due to (i) an increase in clinical research for PAS-004 related to the ongoing FIH Phase 1 Dose Escalation Study and the Phase 1/1b clinical trial of PAS-004 in adult NF1-PN patients, and (ii) an increase in manufacturing costs related to the drug supply for our clinical trials, offset by decreases in pre-clinical research and the reduction in workforce related to the closure of our research laboratory."

Industry Context

Pasithea Therapeutics operates in the highly capital-intensive and high-risk clinical-stage biotechnology sector, focusing on CNS disorders and oncology. The company's strategy to develop a next-generation MEK inhibitor (PAS-004) for MAPK pathway-driven tumors and NF1-PN positions it in a competitive landscape with existing MEK inhibitors and emerging therapies. The ongoing clinical trials for PAS-004, particularly the expansion into NF1-PN, reflect a common biotech strategy of targeting indications with unmet needs. However, like many clinical-stage biotechs, Pasithea faces significant liquidity challenges and relies heavily on external financing, a common characteristic of companies in this development phase where product revenue is still distant. The dissolution of certain subsidiaries and reduction in preclinical research suggest a strategic focus on core clinical assets, a trend seen in companies optimizing resources.

Comparison to Industry Standards

• The company's accumulated deficit of nearly $60 million and recurring operating losses are typical for a clinical-stage biotechnology company that has not yet brought a product to market.
• The reliance on equity and debt financings, including ATM offerings and public offerings, is a standard capital-raising approach for biotechs funding extensive R&D and clinical trials.
• The "going concern" warning is a serious indicator, but not uncommon for early-stage biotechs with no revenue and high burn rates, especially when cash reserves are limited to approximately one year's operating expenses.
• The progress of PAS-004 into Phase 1/1b trials for NF1-PN is a positive clinical milestone, aligning with industry efforts to address rare diseases and specific genetic disorders. For example, other companies like AstraZeneca/Merck (Koselugo) have successfully developed MEK inhibitors for NF1-PN, setting a high bar for efficacy and safety.
• The de-prioritization of discovery programs (PAS-001, PAS-003) and closure of a research laboratory, while impacting R&D expenses, could be seen as a strategic move to conserve capital and focus on the most advanced and promising asset (PAS-004), a common practice in resource-constrained biotechs.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings that, if determined adversely, would have a material adverse effect on the business.

Related Party Transactions

• Consulting Agreement with Prof. Lawrence Steinman, whose compensation was reduced from $25,000 per quarter to $1.00 per quarter, effective October 1, 2025.

Stakeholder Impact

• Shareholders: Significant dilution risk due to ongoing capital raises (ATM, public offerings, warrant exercises) and the need for future funding. Potential for further share price decline given the "going concern" warning and limited cash runway.
• Employees: Workforce reductions related to the closure of the research laboratory have occurred. Stock-based compensation is a component of overall compensation, but the company's financial instability could impact morale and retention.
• Customers (future patients): Continued development of PAS-004 offers potential new treatments for MAPK pathway-driven tumors and NF1-PN, but the company's financial viability poses a risk to the successful completion and commercialization of these programs.
• Creditors: Increased risk due to the "going concern" uncertainty and reliance on equity financing.
• Suppliers/Partners: Potential risk of delayed payments or renegotiated terms if liquidity issues worsen.

Next Steps

• Complete the FIH Phase 1 Dose Escalation Study for PAS-004 in 2026.
• Continue conducting the Phase 1/1b multicenter, open-label, dose escalation trial of PAS-004 in adult NF1-PN patients.
• Aim to conduct a Phase 1 trial for pediatric NF1-PN patients.
• Ultimately complete registrational clinical trials in both adult and pediatric NF1-PN populations.
• Evaluate the provisions and potential impacts of the "One Big Beautiful Bill Act" on consolidated financial statements.
• Obtain additional working capital funding from the sale of equity and/or debt securities.
• Establish a sales, marketing, and distribution infrastructure if drugs are approved.
• Maintain, expand, and protect the intellectual property portfolio.
• Hire additional clinical, scientific, and commercial personnel.
• Add operational, financial, and management information systems and personnel.
• Acquire or in-license or invent other product candidates or technologies.

Key Dates

Recommendation

The explicit "going concern" warning, coupled with a rapidly depleting cash balance ($4.1 million with a burn rate of nearly $10 million in nine months from operations), indicates severe financial distress. While clinical progress is noted, the company's ability to fund these trials to completion is highly questionable without immediate and substantial capital raises, which will likely lead to significant further dilution. The "baby shelf rules" further constrain their ability to raise capital efficiently. The reduction in a key consultant's pay to $1.00 per quarter also signals extreme cost-cutting measures. This presents an exceptionally high-risk investment profile with a strong likelihood of further value erosion.

Keywords

Biotechnology, Clinical-stage, PAS-004, MEK inhibitor, Neurofibromatosis type 1 (NF1), Plexiform neurofibromas (PN), MAPK pathway-driven tumors, CNS disorders, RASopathies, Drug development, Clinical trials, SEC filing, 10-Q, Going concern, Capital raise, Biopharma